1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

Frontier Pharma: Cancer Immunotherapies - First-in-Class Pipeline Dominated by Immunomodulators and PD-1 Like Targets

  • September 2017
  • 135 pages
  • GBI Research
Report ID: 5136762

Summary

Table of Contents

Search Inside

Frontier Pharma: Cancer Immunotherapies - First-in-Class Pipeline Dominated by Immunomodulators and PD-1 Like Targets

Summary
Cancer is a group of diseases that are defined by abnormal cell growth, local tissue invasion and eventual migration to other parts of the body. The diseases are driven by the accumulation of genetic mutations, which provide selective advantages to cells allowing them to evolve and propagate virtually all sites and tissues in the human body.

Cancer currently stands as the second leading cause of death in economically developed countries globally, surpassed only by heart disease (World Health Organization, 2017). Across the eight major developed markets (the US, the UK, France, Germany, Italy, Spain, Japan and Canada) there were a total of 3.6 Million incident cases of cancer, and 11.2 Million five-year prevalent cases across the top 20 most common sites in 2012. Its prevalence across the globe presents a huge health burden, with over 14 Million new cases being diagnosed in 2012, with a five-year prevalence of 32.6 Million.

Approximately 26 Million new cancer cases and 17 Million cancer deaths per year are projected by 2030 (Ferlay et al., 2015). This increase in cancer incidence and mortality is forecast to be driven by population growth and aging across developed and developing countries, with the global population forecast to reach 8.3 billion by 2030.

The two most common cancers by five-year prevalence are prostate and breast cancers, with 696 and 686 prevalent cases per 500,000 respectively. These have 559,000 and 560,000 incident cases each year, respectively. The other most common cancers comprise a variety of sites across almost all organ systems, with only the CNS and skeletal system not being represented among the top 20 cancers by site.

The report “Frontier Pharma: Cancer Immunotherapies - First-in-Class Pipeline Dominated by Immunomodulators and PD-1 Like Targets” is a comprehensive study of disease pathogenesis, diagnosis, prognosis and the treatment options available.

Specifically, this report -

- Visualize the composition of the cancer immunotherapies market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed.
- Analyze the cancer immunotherapies pipeline and stratify by stage of development, molecule type and molecular target.
- Assess the therapeutic potential of first-in-class targets. Using a proprietary molecular target matrix tailored directly towards cancer immunotherapies, first-in-class products have been assessed and ranked according to clinical potential.
- Helps to identify commercial opportunities in the cancer immunotherapies deals landscape by analyzing trends in licensing and co-development deals, and producing a list of first-in-class therapies with no prior involvement in licensing or co-development deals.

Scope
- The 3,100 products in active development, of which 989 are first-in-class and therefore act on completely novel targets, far exceed the scope of the current market. How will pipeline innovation affect the future cancer immunotherapies market?
- There are 322 distinct first-in-class molecular targets currently being studied. Which of these hold the greatest potential to improve future disease treatment with regard to their molecular target?
- Multiple types of cancer immunotherapies exist. Which of these are the most promising, and how does the ratio of first-in-class targets to first-in-class products differ by stage of development and molecular target class?
- A significant number of first-in-class products have been identified with some prior involvement in deals. How do deal frequency and value compare between target families and molecule types, and which first-in-class programs have not yet been involved in a licensing or co-development deal?

Reasons to buy
- Understand the current clinical and commercial landscape. The report includes a comprehensive study of disease pathogenesis, diagnosis, prognosis and the treatment options available.
- Visualize the composition of the cancer immunotherapies market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the market.
- Analyze the cancer immunotherapies pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking immunotherapeutic approaches to treating cancer indications with current poor prognoses, including melanoma and lung cancer.
- Assess the therapeutic potential of first-in-class targets. Using a proprietary molecular target matrix tailored directly towards cancer immunotherapies, first-in-class products have been assessed and ranked according to clinical potential.
- Identify commercial opportunities in the cancer immunotherapies deals landscape by analyzing trends in licensing and co-development deals, and producing a list of first-in-class therapies with no prior involvement in licensing or co-development deals.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

OpportunityAnalyzer: Acute Myeloid Leukemia - Opportunity Analysis and Forecasts to 2026

  • $ 10995
  • Industry report
  • July 2017
  • by GlobalData

OpportunityAnalyzer: Acute Myeloid Leukemia - Opportunity Analysis and Forecasts to 2026 Summary Acute myeloid leukemia (AML) is a rapidly progressing blood cancer with a poor overall prognosis. AML is ...

PharmaFocus: Visual Analysis of Immuno-Oncology Development and Opportunities

  • $ 7995
  • Industry report
  • August 2017
  • by GlobalData

PharmaFocus: Visual Analysis of Immuno-Oncology Development and Opportunities Summary Immuno-Oncology (IO) is uniquely positioned to become the fifth pillar of cancer treatment alongside surgery, radiotherapy, ...

Frontier Pharma: Hematological Disorders - Iron Regulators and Immune Response Targeted Programs Within Anemias and other Red Blood Cell Disorders Hold Potential to Transform Therapy Area with Significant Unmet Need

  • $ 6995
  • Industry report
  • August 2017
  • by GBI Research

Frontier Pharma: Hematological Disorders - Iron Regulators and Immune Response Targeted Programs Within Anemias and other Red Blood Cell Disorders Hold Potential to Transform Therapy Area with Significant ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.